Company intelligence
Brainomix
AI-Enabled Precision Medicine
About Brainomix
We turn ordinary scans into extraordinary insights because every patient deserves expert-level care, anywhere. Brainomix is a global pioneer in AI medical imaging, enabling precision medicine for better treatment decisions in stroke and lung diseases. Our flagship product, Brainomix 360 Stroke, is the world's first fully automated AI-imaging platform, designed for acute stroke assessment at all points of the patient pathway, facilitating more confident treatment and transfer decisions for patients in all hospitals, regardless of local resources or expertise. Brainomix 360 e-Lung automatically identifies and quantifies features on CT lung scans enabling clinicians to more easily identify changes including subtle deteriorations over multiple scan timepoints. Founded as a spinout from the University of Oxford, Brainomix has offices in the UK, Ireland and the USA, and operations in more than 20 countries.
Verified activity
Signals from Brainomix
8 published signals
Research & Knowledge
Brainomix and Endeavor BioMedicines presented positive results from quantitative image analysis of Phase 2a #IPF Trial at ERS2026 using AI-powered quantitative CT analysis with e-Lung in the ENV-IPF-101 Phase 2a trial of taladegib.
Reported by Brainomix
Customers & Market
Brainomix software helped the stroke team make critical treatment decisions in real time within 8 minutes of arriving in A&E for a stroke patient at the Royal Berkshire NHS Foundation Trust.
Reported by Brainomix
Presence & Recognition
Brainomix team is attending the ERS2026 event in Barcelona this week
Reported by Riaz Rahman
Presence & Recognition
Brainomix worked with Royal Berkshire NHS Foundation Trust to treat stroke care
Reported by George Harston
Research & Knowledge
Brainomix is presenting new research on how quantitative CT could provide objective insights to support risk stratification and identify pulmonary hypertension in ILD.
Reported by Brainomix
Research & Knowledge
Brainomix published research findings exploring the potential of its lung imaging biomarkers to predict future FVC decline and clinical trials.
Reported by Brainomix
Presence & Recognition
Brainomix is hosting the ESMINT Conference in the south of France.
Reported by Riaz Rahman
Presence & Recognition
Brainomix team members George Harston, Patricia Rodriguez Crespo, Matt Proctor and Emma Houtz are on-site at ESMINT 2026 in Marseille alongside partner Medtronic Neurovascular.
Reported by Brainomix